These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39018772)

  • 1. Multi-omics profiling to identify early plasma biomarkers in pre-diagnostic pancreatic ductal adenocarcinoma: a nested case-control study.
    Borgmästars E; Ulfenborg B; Johansson M; Jonsson P; Billing O; Franklin O; Lundin C; Jacobson S; Simm M; Lubovac-Pilav Z; Sund M
    Transl Oncol; 2024 Oct; 48():102059. PubMed ID: 39018772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y; Holmes MV; Chen Z; Kartsonaki C
    J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma.
    Mishra NK; Southekal S; Guda C
    Front Genet; 2019; 10():624. PubMed ID: 31379917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples.
    Borgmästars E; Lundberg E; Öhlund D; Nyström H; Franklin O; Lundin C; Jonsson P; Sund M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma.
    Liu X; Wang W; Liu X; Zhang Z; Yu L; Li R; Guo D; Cai W; Quan X; Wu H; Dai M; Liang Z
    Clin Transl Med; 2022 Jan; 12(1):e670. PubMed ID: 35061935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
    Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
    Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma.
    Zhao G; Jiang R; Shi Y; Gao S; Wang D; Li Z; Zhou Y; Sun J; Wu W; Peng J; Kuang T; Rong Y; Yuan J; Zhu S; Jin G; Wang Y; Lou W
    Mol Oncol; 2024 Apr; ():. PubMed ID: 38561976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
    Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
    Rajamani D; Bhasin MK
    Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.
    Martín-Blázquez A; Jiménez-Luna C; Díaz C; Martínez-Galán J; Prados J; Vicente F; Melguizo C; Genilloud O; Pérez Del Palacio J; Caba O
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
    Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
    Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
    Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics for early pancreatic cancer detection in plasma samples from a Swedish prospective population-based biobank.
    Borgmästars E; Jacobson S; Simm M; Johansson M; Billing O; Lundin C; Nyström H; Öhlund D; Lubovac-Pilav Z; Jonsson P; Franklin O; Sund M
    J Gastrointest Oncol; 2024 Apr; 15(2):755-767. PubMed ID: 38756646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma.
    Cao Y; Zhao R; Guo K; Ren S; Zhang Y; Lu Z; Tian L; Li T; Chen X; Wang Z
    Front Oncol; 2021; 11():744667. PubMed ID: 35127469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T; Dujon AM; Taly V; Dunyach-Remy C; Lavigne JP; Costa-Silva B; Kurma K; Eslami-S Z; Cayrefourcq L; Canivet C; Muscari F; Bournet B; Alix-Panabières C
    BMC Cancer; 2024 Jun; 24(1):709. PubMed ID: 38853244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
    SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.